2190 Share Price Performance
HK$19.18
-5.22 (-21.39%)
37.8% undervalued intrinsic discount
HK$30.85
Fair Value
Price HK$19.18
everyseed HK$30.85
Fair ValueHK$30.85
Share Pricen/a
New Narrative • Jun 29
Zylox-Tonbridge Medical Technology Co., Ltd. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
2190 Community Narratives
EV
Fair Value
·Fair Value HK$30.85 37.8% undervalued intrinsic discount
Zylox-Tonbridge: Early Signs of an Emerging Global Vascular Intervention Platform
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Zylox-Tonbridge: Early Signs of an Emerging Global Vascular Intervention Platform
Zylox-Tonbridge is starting to show signs that its medical devices are moving from overseas buzz to real use in hospitals, with doctors trying multiple products across several countries. If those early wins turn into repeat buying, it could help the company rely less on a tough, price-pressured home market—but the next steps will matter.Read more
EV
HK$30.85
37.8% undervalued intrinsic discount
Fair Value
Revenue
28% p.a.
Profit Margin
21%
Future PE
20x
Price in 2031
HK$44.32
Trending Discussion
No trending discussion available.
Recently Updated Narratives
EV
Zylox-Tonbridge: Early Signs of an Emerging Global Vascular Intervention Platform
Fair Value: HK$30.85 37.8% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Zylox-Tonbridge Medical Technology Co., Ltd. Key Details
About 2190
- Founded
- 2012
- Employees
- 925
- CEO
- WebsiteView website
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People’s Republic of China and internationally. It offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. The company’s peripheral-vascular interventional product portfolio includes stents, balloons, catheters, and filters, as well as covers hemodialysis access, arterial, venous, peripheral embolization intervention, and other intervention products. In addition, the company provides technical consultation and services, as well as imports materials. It serves patients and physicians. The company was formerly known as Zhejiang Zylox Medical Device Co., Ltd. and changed its name to Zylox-Tonbridge Medical Technology Co., Ltd. in March 2021. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Hangzhou, the People’s Republic of China.
